Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2321350 | 0.93 | VDR (0.59) | VDRAR | |
| SCHEMBL2321242 | 0.92 | VDR (0.58) | VDRAR | |
| SCHEMBL2325769 | 0.91 | VDR (0.57) | VDRAR | |
| SCHEMBL2325365 | 0.90 | VDR (0.56) | VDRAR | |
| SCHEMBL2317577 | 0.89 | VDR (0.53) | VDRAR | |
| SCHEMBL2316957 | 0.85 | HDAC6 (0.52) | VDRAR | |
| SCHEMBL2319860 | 0.84 | VDR (0.58) | VDRAR | |
| SCHEMBL2320783 | 0.83 | VDR (0.57) | VDRAR | |
| SCHEMBL3859969 | 0.83 | VDR (0.61) | VDRAR | |
| SCHEMBL2323415 | 0.83 | VDR (0.56) | VDRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836177-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-1836177-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2011-08-10 | — | — | EP | disclosed |
| US-7659296-B2 | 2-{1-[4-(3,3-dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-1-ethyl-propyl}-benzooxazole-6-carboxylic acid; 1-[4-(3,3-Dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-1-ethyl-propyl}-benzooxazole-6-carboxylic acid amide; stimulate bone formation, restore bone quality, acne, alopecia, Alzheimer's disease etc. | ELI LILLY AND COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659296-B2 | 2-{1-[4-(3,3-dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-1-ethyl-propyl}-benzooxazole-6-carboxylic acid; 1-[4-(3,3-Dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-1-ethyl-propyl}-benzooxazole-6-carboxylic acid amide; stimulate bone formation, restore bone quality, acne, alopecia, Alzheimer's disease etc. | ELI LILLY AND COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659296-B2 | 2-{1-[4-(3,3-dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-1-ethyl-propyl}-benzooxazole-6-carboxylic acid; 1-[4-(3,3-Dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-1-ethyl-propyl}-benzooxazole-6-carboxylic acid amide; stimulate bone formation, restore bone quality, acne, alopecia, Alzheimer's disease etc. | ELI LILLY AND COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-20080119407-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080119407-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080119407-A1 | Vitamin D Receptor Modulators | ELI LILLY AND COMPANY | 2008-05-22 | — | — | US | disclosed |
| EP-1836177-A2 | VITAMIN D RECEPTOR MODULATORS | Eli Lilly and Company (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069154-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119407-A1 | Vitamin D Receptor Modulators | VDR, CYP2R1, CYP24A1 | VDR 1/4885AR 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.